[Federal Register Volume 75, Number 190 (Friday, October 1, 2010)]
[Notices]
[Page 60761]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-24679]
[[Page 60761]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Inhibitors of 6-hydroxymethyl-7,8-dihydropterin Pyrophosphokinase as
Novel Antibiotics
Description of Invention: The invention offered for licensing
describes and claims novel inhibitors of 6-hydroxymethyl-7,8-
dihydropterin pyrophosphokinase (HPPK), a key enzyme in the folate
biosynthetic pathway which is essential for microorganisms but absent
in mammals. These novel inhibitors are based on linked purine pterin
compounds. They can disrupt the folate biosynthesis of bacteria and
thus can find utility as potential antimicrobials. Antibiotics based on
these lead molecules can be specifically designed and synthesized to
serve as broad-spectrum or narrow-spectrum antibiotics. None of the
currently established antibiotics target HPPK.
Applications:
Antimicrobial agents.
Use in anti-bioterrorism.
Advantages:
Potential as broad-spectrum or narrow-spectrum
antibiotics.
The antibiotics of present invention target a new
biological pathway that has not been targeted by existing antibiotics,
and thus circumvent issues related to drug resistance.
Inventors: Genbin Shi, Gary Shaw, Xinhua Ji (NCI).
Patent Status: U.S. Provisional Application No. 61/356,213 filed 18
Jun 2010 (HHS Reference No. E-170-2010/0-US-01).
Relevant Publications:
1. Blaszczyk J, Shi G, Li Y, Yan H, Ji X. Reaction trajectory of
pyrophosphoryl transfer catalyzed by 6-hydroxymethyl-7,8-dihydropterin
pyrophosphokinase. Structure 2004 Mar;12(3):467-475. [PubMed:
15016362].
2. Blaszczyk J, Shi G, Yan H, Ji X. Catalytic center assembly of
HPPK as revealed by the crystal structure of a ternary complex at 1.25A
resolution. Structure 2000 Oct 15; 8(10):1049-1058. [PubMed:
11080626].
3. Wood HCS. 1975. Specific inhibition of dihydrofolate
biosynthesis--a new approach to chemotherapy. Chemistry and Biology of
Pteridines, W. Pfleiderer, ed. (Berlin-New York: Walter de Gruyter).
Licensing Status: Available for licensing.
Licensing Contacts:
Uri Reichman, Ph.D., MBA; 301-435-4616; [email protected].
John Stansberry, Ph.D.; 301-435-5236; [email protected].
Collaborative Research Opportunity: The National Cancer Institute,
Biomolecular Structure Section, is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the inhibitors of HPPK as novel
antibiotics. Please contact John Hewes, PhD at 301-435-3121 or
[email protected] for more information.
Compositions and Methods for the Treatment of Cancer
Description of Invention: Cancer is the second leading cause of
human death next to coronary disease in the United States. Worldwide,
millions of people die from cancer every year. In the United States
alone, as reported by the American Cancer Society, cancer causes the
death of well over a half-million people annually, with over 1.2
million new cases diagnosed per year. While deaths from heart disease
have been declining significantly, those resulting from cancer
generally are on the rise. Cancer is soon predicted to become the
leading cause of death in the United States.
This application claims methods for inducing an immune response to
a tumor. These methods include administering a therapeutically
effective amount of apoptotic tumor cells conjugated to a K-type CpG
oligodeoxynucleotide (ODN) to a subject. Methods for treating a tumor
in a subject are also claimed in this application. These methods
include administering a therapeutically effective amount of apoptotic
tumor cells conjugated to a K-type CpG oligodeoxynucleotide (ODN) to a
subject. More specifically, the tumor cells may be autologous, and the
tumor may be a lymphoma, cervical cancer, prostate cancer, breast
cancer, colon cancer, or a lung cancer.
Applications:
Vaccines for the prevention of cancer and other
indications
Use of CpG oligonucleotides for prophylaxis and/or therapy
Advantages:
Novel vaccine candidates
Increased immunogenicity
Development Status: Preclinical studies have been conducted by the
inventors.
Inventors: Dennis M. Klinman and Hidekazu Shirota (NCI).
Patent Status: U.S. Provisional Application No. 61/309,802 filed 02
Mar 2010 (HHS Reference No. E-266-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Peter A. Soukas; 301-435-4646;
[email protected].
Collaborative Research Opportunity: The Center for Cancer Research,
Laboratory of Experimental Immunology, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact John Hewes, Ph.D. at 301-435-3121 or
[email protected] for more information.
Dated: September 27, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-24679 Filed 9-30-10; 8:45 am]
BILLING CODE 4140-01-P